Cargando…

A microfluidic biosensor architecture for the rapid detection of COVID-19

The lack of enough diagnostic capacity to detect severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has been one of the major challenges in the control the 2019 COVID pandemic; this led to significant delay in prompt treatment of COVID-19 patients or accurately estimate disease situation....

Descripción completa

Detalles Bibliográficos
Autores principales: Muhsin, Sura A., He, Ying, Al-Amidie, Muthana, Sergovia, Karen, Abdullah, Amjed, Wang, Yang, Alkorjia, Omar, Hulsey, Robert A., Hunter, Gary L., Erdal, Zeynep K., Pletka, Ryan J., Hyleme, S. George, Wan, Xiu-Feng, Almasri, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251744/
https://www.ncbi.nlm.nih.gov/pubmed/37524456
http://dx.doi.org/10.1016/j.aca.2023.341378
_version_ 1785056007735476224
author Muhsin, Sura A.
He, Ying
Al-Amidie, Muthana
Sergovia, Karen
Abdullah, Amjed
Wang, Yang
Alkorjia, Omar
Hulsey, Robert A.
Hunter, Gary L.
Erdal, Zeynep K.
Pletka, Ryan J.
Hyleme, S. George
Wan, Xiu-Feng
Almasri, Mahmoud
author_facet Muhsin, Sura A.
He, Ying
Al-Amidie, Muthana
Sergovia, Karen
Abdullah, Amjed
Wang, Yang
Alkorjia, Omar
Hulsey, Robert A.
Hunter, Gary L.
Erdal, Zeynep K.
Pletka, Ryan J.
Hyleme, S. George
Wan, Xiu-Feng
Almasri, Mahmoud
author_sort Muhsin, Sura A.
collection PubMed
description The lack of enough diagnostic capacity to detect severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has been one of the major challenges in the control the 2019 COVID pandemic; this led to significant delay in prompt treatment of COVID-19 patients or accurately estimate disease situation. Current methods for the diagnosis of SARS-COV-2 infection on clinical specimens (e.g. nasal swabs) include polymerase chain reaction (PCR) based methods, such as real-time reverse transcription (rRT) PCR, real-time reverse transcription loop-mediated isothermal amplification (rRT-LAMP), and immunoassay based methods, such as rapid antigen test (RAT). These conventional PCR methods excel in sensitivity and specificity but require a laboratory setting and typically take up to six hours to obtain the results whereas RAT has a low sensitivity (typically at least 3000 TCID50/ml) although with the results with 15 mins. We have developed a robust micro-electro-mechanical system (MEMS) based impedance biosensor fit for rapid and accurate detection of SARS-COV-2 of clinical samples in the field with minimal training. The biosensor consisted of three regions that enabled concentrating, trapping, and sensing the virus present in low quantities with high selectivity and sensitivity in 40 minutes using an electrode coated with a specific SARS-COV-2 antibody cross-linker mixture. Changes in the impedance value due to the binding of the SARS-COV-2 antigen to the antibody will indicate positive or negative result. The testing results showed that the biosensor's limit of detection (LoD) for detection of inactivated SARS-COV-2 antigen in phosphate buffer saline (PBS) was as low as 50 TCID50/ml. The biosensor specificity was confirmed using the influenza virus while the selectivity was confirmed using influenza polyclonal sera. Overall, the results showed that the biosensor is able to detect SARS-COV-2 in clinical samples (swabs) in 40 min with a sensitivity of 26 TCID50/ml.
format Online
Article
Text
id pubmed-10251744
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-102517442023-06-12 A microfluidic biosensor architecture for the rapid detection of COVID-19 Muhsin, Sura A. He, Ying Al-Amidie, Muthana Sergovia, Karen Abdullah, Amjed Wang, Yang Alkorjia, Omar Hulsey, Robert A. Hunter, Gary L. Erdal, Zeynep K. Pletka, Ryan J. Hyleme, S. George Wan, Xiu-Feng Almasri, Mahmoud Anal Chim Acta Article The lack of enough diagnostic capacity to detect severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has been one of the major challenges in the control the 2019 COVID pandemic; this led to significant delay in prompt treatment of COVID-19 patients or accurately estimate disease situation. Current methods for the diagnosis of SARS-COV-2 infection on clinical specimens (e.g. nasal swabs) include polymerase chain reaction (PCR) based methods, such as real-time reverse transcription (rRT) PCR, real-time reverse transcription loop-mediated isothermal amplification (rRT-LAMP), and immunoassay based methods, such as rapid antigen test (RAT). These conventional PCR methods excel in sensitivity and specificity but require a laboratory setting and typically take up to six hours to obtain the results whereas RAT has a low sensitivity (typically at least 3000 TCID50/ml) although with the results with 15 mins. We have developed a robust micro-electro-mechanical system (MEMS) based impedance biosensor fit for rapid and accurate detection of SARS-COV-2 of clinical samples in the field with minimal training. The biosensor consisted of three regions that enabled concentrating, trapping, and sensing the virus present in low quantities with high selectivity and sensitivity in 40 minutes using an electrode coated with a specific SARS-COV-2 antibody cross-linker mixture. Changes in the impedance value due to the binding of the SARS-COV-2 antigen to the antibody will indicate positive or negative result. The testing results showed that the biosensor's limit of detection (LoD) for detection of inactivated SARS-COV-2 antigen in phosphate buffer saline (PBS) was as low as 50 TCID50/ml. The biosensor specificity was confirmed using the influenza virus while the selectivity was confirmed using influenza polyclonal sera. Overall, the results showed that the biosensor is able to detect SARS-COV-2 in clinical samples (swabs) in 40 min with a sensitivity of 26 TCID50/ml. Published by Elsevier B.V. 2023-06-09 /pmc/articles/PMC10251744/ /pubmed/37524456 http://dx.doi.org/10.1016/j.aca.2023.341378 Text en © 2023 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Muhsin, Sura A.
He, Ying
Al-Amidie, Muthana
Sergovia, Karen
Abdullah, Amjed
Wang, Yang
Alkorjia, Omar
Hulsey, Robert A.
Hunter, Gary L.
Erdal, Zeynep K.
Pletka, Ryan J.
Hyleme, S. George
Wan, Xiu-Feng
Almasri, Mahmoud
A microfluidic biosensor architecture for the rapid detection of COVID-19
title A microfluidic biosensor architecture for the rapid detection of COVID-19
title_full A microfluidic biosensor architecture for the rapid detection of COVID-19
title_fullStr A microfluidic biosensor architecture for the rapid detection of COVID-19
title_full_unstemmed A microfluidic biosensor architecture for the rapid detection of COVID-19
title_short A microfluidic biosensor architecture for the rapid detection of COVID-19
title_sort microfluidic biosensor architecture for the rapid detection of covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251744/
https://www.ncbi.nlm.nih.gov/pubmed/37524456
http://dx.doi.org/10.1016/j.aca.2023.341378
work_keys_str_mv AT muhsinsuraa amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT heying amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT alamidiemuthana amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT sergoviakaren amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT abdullahamjed amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT wangyang amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT alkorjiaomar amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT hulseyroberta amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT huntergaryl amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT erdalzeynepk amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT pletkaryanj amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT hylemesgeorge amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT wanxiufeng amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT almasrimahmoud amicrofluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT muhsinsuraa microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT heying microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT alamidiemuthana microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT sergoviakaren microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT abdullahamjed microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT wangyang microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT alkorjiaomar microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT hulseyroberta microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT huntergaryl microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT erdalzeynepk microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT pletkaryanj microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT hylemesgeorge microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT wanxiufeng microfluidicbiosensorarchitecturefortherapiddetectionofcovid19
AT almasrimahmoud microfluidicbiosensorarchitecturefortherapiddetectionofcovid19